Companies › Pharmanutra
1 active drug program in 1 registered trial: 1 Phase 4; Hematology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sucrosomial® Iron (Sideral® Forte) Dietary iron supplement with sucrosomial delivery technology | IRON | Phase 4 | Anemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07308769 | Sucrosomial® Iron (Sideral® Forte) | Phase 4 | Anemia | Hematology | Oct 2026 |
–
Vega Therapeutics VarmX MIBIO PTE. Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.